Company Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy.
It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
| Country | France |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Daniel Tassé |
Contact Details
Address: Bâtiment IRO, 107 Av. de la République Châtillon, 92320 France | |
| Phone | 33 1 55 42 78 78 |
| Website | dbv-technologies.com |
Stock Details
| Ticker Symbol | DBVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001613780 |
| CUSIP Number | 23306J101 |
| ISIN Number | US23306J3095 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel Tassé | Chief Executive Officer and Director |
| Virginie Simone Jeanine Verrechia Boucinha M.B.A. | Chief Financial Officer |
| Dr. Pharis Mohideen M.D. | Chief Medical Officer |
| Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer |
| Michele F. Robertson | Chief Legal Officer |
| James Briggs | Chief Human Resources Officer |
| Caroline Daniere | Chief of Staff |
| Alan Kerr | Senior Vice President and Head of Global Regulatory Affairs |
| Pascal Wotling | Chief External Manufacturing and Supply Chain Officer |
| Dr. Robert G. Pietrusko Pharm. D., Pharm.D. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | SCHEDULE 13G | Filing |
| Jul 29, 2025 | 8-K | Current Report |
| Jul 29, 2025 | 10-Q | Quarterly Report |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 11, 2025 | 8-K | Current Report |
| May 29, 2025 | EFFECT | Notice of Effectiveness |
| May 29, 2025 | 424B3 | Prospectus |
| May 23, 2025 | UPLOAD | Filing |
| May 19, 2025 | S-3 | Registration statement under Securities Act of 1933 |